| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 16 | 2024 | 144 | 2.590 |
Why?
|
| Ubiquitin Thiolesterase | 8 | 2023 | 52 | 1.520 |
Why?
|
| Tumor Suppressor Proteins | 10 | 2024 | 194 | 1.500 |
Why?
|
| Brain Neoplasms | 10 | 2017 | 111 | 1.130 |
Why?
|
| Lung Neoplasms | 8 | 2022 | 358 | 1.090 |
Why?
|
| HMGB1 Protein | 5 | 2023 | 29 | 0.880 |
Why?
|
| Asbestos | 6 | 2024 | 55 | 0.820 |
Why?
|
| Pleural Neoplasms | 3 | 2016 | 53 | 0.800 |
Why?
|
| Glioblastoma | 8 | 2017 | 55 | 0.780 |
Why?
|
| Glioma | 5 | 2015 | 79 | 0.610 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 88 | 0.610 |
Why?
|
| Cell Nucleus | 4 | 2021 | 366 | 0.580 |
Why?
|
| Germ-Line Mutation | 5 | 2024 | 57 | 0.550 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 628 | 0.480 |
Why?
|
| Mutation | 7 | 2023 | 1095 | 0.440 |
Why?
|
| Phosphoproteins | 2 | 2010 | 163 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2020 | 172 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 182 | 0.370 |
Why?
|
| Mice | 26 | 2023 | 5913 | 0.360 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 55 | 0.350 |
Why?
|
| Melanoma | 2 | 2022 | 96 | 0.310 |
Why?
|
| Molecular Biology | 1 | 2008 | 46 | 0.300 |
Why?
|
| Animals | 29 | 2023 | 15081 | 0.280 |
Why?
|
| Calcium Signaling | 2 | 2024 | 101 | 0.260 |
Why?
|
| Picolinic Acids | 6 | 2006 | 12 | 0.250 |
Why?
|
| Humans | 36 | 2024 | 37093 | 0.240 |
Why?
|
| Signal Transduction | 5 | 2017 | 1908 | 0.240 |
Why?
|
| Mitochondria | 3 | 2017 | 487 | 0.240 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 75 | 0.230 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2023 | 84 | 0.230 |
Why?
|
| Antineoplastic Agents | 6 | 2017 | 803 | 0.230 |
Why?
|
| DNA Repair | 1 | 2024 | 188 | 0.220 |
Why?
|
| Histone Deacetylase 1 | 1 | 2021 | 15 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2017 | 807 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 54 | 0.200 |
Why?
|
| Epithelial Cells | 3 | 2020 | 384 | 0.200 |
Why?
|
| Apoptosis | 7 | 2024 | 1398 | 0.200 |
Why?
|
| Autophagy | 2 | 2020 | 116 | 0.200 |
Why?
|
| Asbestosis | 1 | 2020 | 6 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2017 | 259 | 0.190 |
Why?
|
| Heterozygote | 4 | 2023 | 93 | 0.190 |
Why?
|
| RecQ Helicases | 1 | 2020 | 35 | 0.180 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 159 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 8 | 2017 | 502 | 0.180 |
Why?
|
| Cell Hypoxia | 5 | 2011 | 58 | 0.180 |
Why?
|
| Cell Line, Tumor | 11 | 2017 | 2231 | 0.180 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 893 | 0.170 |
Why?
|
| Biopsy | 2 | 2016 | 164 | 0.170 |
Why?
|
| Macrophages | 5 | 2006 | 439 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 93 | 0.160 |
Why?
|
| Cell Proliferation | 6 | 2017 | 1198 | 0.160 |
Why?
|
| Cell Survival | 7 | 2017 | 864 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 562 | 0.150 |
Why?
|
| Mice, Knockout | 4 | 2020 | 933 | 0.150 |
Why?
|
| Endothelial Cells | 3 | 2011 | 308 | 0.150 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 9 | 0.150 |
Why?
|
| Stem Cell Factor | 2 | 2008 | 4 | 0.150 |
Why?
|
| Pyruvates | 1 | 2017 | 6 | 0.150 |
Why?
|
| Guanidines | 1 | 2017 | 17 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 17 | 0.140 |
Why?
|
| Cytoplasm | 1 | 2017 | 143 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 92 | 0.140 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 105 | 0.140 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 56 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 80 | 0.140 |
Why?
|
| Magnesium Compounds | 1 | 2016 | 2 | 0.140 |
Why?
|
| Silicon Compounds | 1 | 2016 | 6 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 217 | 0.140 |
Why?
|
| Uveal Neoplasms | 1 | 2015 | 9 | 0.130 |
Why?
|
| Macrophage Activation | 4 | 2004 | 56 | 0.130 |
Why?
|
| Drug Design | 1 | 2017 | 162 | 0.130 |
Why?
|
| Mice, SCID | 5 | 2017 | 150 | 0.130 |
Why?
|
| Protein Binding | 5 | 2021 | 972 | 0.130 |
Why?
|
| Glutamine | 1 | 2015 | 40 | 0.120 |
Why?
|
| Interferon-gamma | 4 | 2004 | 250 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 360 | 0.120 |
Why?
|
| Prognosis | 4 | 2021 | 739 | 0.120 |
Why?
|
| Calcium | 1 | 2017 | 480 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 22 | 0.120 |
Why?
|
| Drug Approval | 1 | 2014 | 8 | 0.120 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 107 | 0.120 |
Why?
|
| Down-Regulation | 5 | 2014 | 435 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 113 | 0.120 |
Why?
|
| Staurosporine | 1 | 2013 | 38 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 37 | 0.120 |
Why?
|
| Nanocapsules | 1 | 2013 | 17 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2016 | 216 | 0.120 |
Why?
|
| Piperidines | 2 | 2004 | 77 | 0.110 |
Why?
|
| Inflammation | 3 | 2023 | 618 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 5 | 2010 | 1609 | 0.110 |
Why?
|
| Flavonoids | 2 | 2004 | 87 | 0.110 |
Why?
|
| Liposomes | 1 | 2013 | 118 | 0.110 |
Why?
|
| Protein Kinase C | 1 | 2013 | 120 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2015 | 305 | 0.110 |
Why?
|
| Neuroblastoma | 2 | 2004 | 129 | 0.110 |
Why?
|
| Genomic Instability | 2 | 2024 | 38 | 0.110 |
Why?
|
| Mice, Nude | 4 | 2017 | 337 | 0.110 |
Why?
|
| Incidence | 3 | 2021 | 922 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 147 | 0.100 |
Why?
|
| Female | 11 | 2024 | 20969 | 0.100 |
Why?
|
| Cell Transdifferentiation | 1 | 2011 | 8 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 53 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 78 | 0.090 |
Why?
|
| Middle Aged | 6 | 2024 | 10129 | 0.090 |
Why?
|
| Jurkat Cells | 1 | 2010 | 79 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 59 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2020 | 1518 | 0.090 |
Why?
|
| Male | 8 | 2024 | 20025 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 251 | 0.090 |
Why?
|
| Interleukin-2 | 1 | 2010 | 89 | 0.090 |
Why?
|
| Fibroblasts | 2 | 2024 | 272 | 0.090 |
Why?
|
| Ubiquitin | 2 | 2021 | 78 | 0.080 |
Why?
|
| Aged | 5 | 2020 | 6741 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 32 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 15 | 0.080 |
Why?
|
| Cell Line | 5 | 2015 | 1354 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 41 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 661 | 0.080 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2007 | 22 | 0.080 |
Why?
|
| Nitrosourea Compounds | 1 | 2007 | 1 | 0.080 |
Why?
|
| Stathmin | 1 | 2007 | 2 | 0.070 |
Why?
|
| Oligodendroglioma | 1 | 2007 | 5 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 11 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 43 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 357 | 0.070 |
Why?
|
| Uterus | 1 | 2007 | 55 | 0.070 |
Why?
|
| Moloney murine leukemia virus | 1 | 2006 | 7 | 0.070 |
Why?
|
| Glucose | 1 | 2008 | 230 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 187 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2012 | 426 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2017 | 45 | 0.070 |
Why?
|
| Macrophage Inflammatory Proteins | 2 | 2003 | 16 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 68 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 169 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 43 | 0.070 |
Why?
|
| RNA, Messenger | 5 | 2016 | 1207 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2006 | 110 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2008 | 184 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2008 | 339 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 222 | 0.060 |
Why?
|
| Genes, myc | 1 | 2004 | 29 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 26 | 0.060 |
Why?
|
| Alleles | 2 | 2016 | 321 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2005 | 106 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 144 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 1371 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2007 | 587 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2017 | 362 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2015 | 77 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 85 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 5 | 0.050 |
Why?
|
| Adult | 4 | 2020 | 11712 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 13 | 0.050 |
Why?
|
| Spheroids, Cellular | 2 | 2014 | 28 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2017 | 41 | 0.050 |
Why?
|
| Tryptophan | 1 | 2003 | 73 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 213 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2011 | 928 | 0.050 |
Why?
|
| Genome, Human | 2 | 2016 | 135 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 935 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 306 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 356 | 0.050 |
Why?
|
| Fungi | 1 | 2002 | 89 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2005 | 517 | 0.050 |
Why?
|
| Asbestos, Crocidolite | 1 | 2020 | 8 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 1015 | 0.050 |
Why?
|
| RNA, Small Interfering | 3 | 2008 | 409 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2005 | 681 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2020 | 79 | 0.040 |
Why?
|
| RNA Interference | 2 | 2015 | 243 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 90 | 0.040 |
Why?
|
| Family | 1 | 2020 | 173 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2013 | 195 | 0.040 |
Why?
|
| Neurons | 1 | 2006 | 1175 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 1346 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 481 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 2017 | 22 | 0.040 |
Why?
|
| Protein Stability | 1 | 2017 | 45 | 0.040 |
Why?
|
| Transcription, Genetic | 3 | 2006 | 578 | 0.040 |
Why?
|
| Epithelium | 1 | 2017 | 79 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 28 | 0.040 |
Why?
|
| Germ Cells | 1 | 2017 | 73 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 45 | 0.040 |
Why?
|
| Multigene Family | 1 | 2016 | 106 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 275 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 161 | 0.030 |
Why?
|
| Caspases | 2 | 2008 | 147 | 0.030 |
Why?
|
| Nevada | 1 | 2016 | 6 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2016 | 8 | 0.030 |
Why?
|
| Genealogy and Heraldry | 1 | 2015 | 5 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 174 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 24 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 79 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2017 | 389 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 151 | 0.030 |
Why?
|
| Osteopontin | 1 | 2016 | 36 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 98 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 67 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2017 | 492 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2007 | 444 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2015 | 6 | 0.030 |
Why?
|
| New York | 1 | 2015 | 71 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 4268 | 0.030 |
Why?
|
| DNA Damage | 1 | 2017 | 352 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 176 | 0.030 |
Why?
|
| United States | 2 | 2015 | 4223 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2015 | 172 | 0.030 |
Why?
|
| Camptothecin | 1 | 2014 | 20 | 0.030 |
Why?
|
| Diffusion | 1 | 2013 | 50 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 126 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 113 | 0.030 |
Why?
|
| Quinolines | 1 | 2014 | 64 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 571 | 0.030 |
Why?
|
| Deferoxamine | 2 | 2004 | 19 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 177 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 623 | 0.030 |
Why?
|
| Chemokine CCL3 | 2 | 2003 | 14 | 0.030 |
Why?
|
| Chemokine CCL4 | 2 | 2003 | 19 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2014 | 162 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 61 | 0.030 |
Why?
|
| Quinazolines | 1 | 2011 | 33 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 88 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 9 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2011 | 19 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 2011 | 20 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 166 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 122 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1039 | 0.020 |
Why?
|
| Brain Edema | 1 | 2011 | 63 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2011 | 58 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 127 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 290 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1369 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 10 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 767 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 108 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2026 | 0.020 |
Why?
|
| COS Cells | 1 | 2007 | 69 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2008 | 88 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 73 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2008 | 77 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 227 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 212 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 53 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 26 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 208 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 78 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 307 | 0.020 |
Why?
|
| Terminal Repeat Sequences | 1 | 2006 | 8 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 448 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 188 | 0.020 |
Why?
|
| Hela Cells | 1 | 2007 | 366 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 286 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2006 | 19 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 14 | 0.020 |
Why?
|
| Serum | 1 | 2006 | 15 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2006 | 158 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2006 | 33 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 859 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 617 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2005 | 17 | 0.020 |
Why?
|
| Survival Rate | 1 | 2006 | 311 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 24 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2004 | 36 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 122 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 27 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 997 | 0.020 |
Why?
|
| G2 Phase | 1 | 2004 | 29 | 0.020 |
Why?
|
| G1 Phase | 1 | 2004 | 33 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2004 | 53 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 133 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2005 | 76 | 0.020 |
Why?
|
| Thiazoles | 1 | 2004 | 74 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 98 | 0.010 |
Why?
|
| RNA Stability | 1 | 2004 | 26 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 515 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1568 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 349 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 730 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 689 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 2002 | 4 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 36 | 0.010 |
Why?
|
| Half-Life | 1 | 2002 | 54 | 0.010 |
Why?
|
| Macrophages, Peritoneal | 1 | 2002 | 23 | 0.010 |
Why?
|
| Oxygen | 1 | 2004 | 207 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 91 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 72 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 6 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 433 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 677 | 0.010 |
Why?
|
| Aging | 1 | 2007 | 664 | 0.010 |
Why?
|
| Ferrous Compounds | 1 | 2002 | 20 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2002 | 75 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 626 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 2002 | 21 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 220 | 0.010 |
Why?
|
| Mycoses | 1 | 2002 | 30 | 0.010 |
Why?
|
| Chemokines | 1 | 2003 | 97 | 0.010 |
Why?
|
| Protein Engineering | 1 | 2002 | 44 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1180 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 1549 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 2002 | 56 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 128 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 574 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 515 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2002 | 148 | 0.010 |
Why?
|
| Candida albicans | 1 | 2002 | 164 | 0.010 |
Why?
|
| Microglia | 1 | 2002 | 166 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 674 | 0.010 |
Why?
|